Subcutaneous HBIG Administration for Self-Service Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis B immunoglobulin (HBIG) administration routes, such as intravenous and intramuscular, have limitations including the need for trained medical personnel, potential for infection, and pain at injection sites, which can lead to poor compliance and complications, especially in orthotopic liver transplantation patients who require lifelong prophylaxis against hepatitis B virus recurrence.
Innovation Solution
A subcutaneous HBIG administration method using a dose at least 1.5 to 2.5 times higher than the intramuscular dose, administered via injection, to achieve similar or higher anti-hepatitis B antibody levels and timing as intramuscular administration, allowing for self-administration and reduced hospital visits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous or intramuscular HBIG administration is used, then effective anti-hepatitis B antibody levels are achieved, but the need for trained medical personnel and potential for infection increases
Solution Approach 1:
The patent enables patients to self-administer HBIG via subcutaneous injection at home without requiring trained medical personnel. The formulation is specifically designed for self-injection, allowing patients to independently manage their prophylaxis treatment while maintaining effective antibody delivery to prevent hepatitis B recurrence.
2Reliability
If intramuscular HBIG administration is used, then effective anti-hepatitis B antibody levels are achieved, but pain at injection sites and poor compliance occur
Solution Approach 1:
The patent changes the administration route from intramuscular to subcutaneous injection and modifies the formulation parameters (concentration, volume, pH) to optimize for subcutaneous delivery. This parameter change reduces injection pain and improves patient compliance while maintaining effective anti-hepatitis B antibody levels through the modified release kinetics from the subcutaneous space.
3Ease of operation
If subcutaneous HBIG administration is used with standard intramuscular dosing, then ease of self-administration is improved, but inadequate anti-hepatitis B antibody levels are achieved
Solution Approach 1:
The patent determines optimal subcutaneous dosing parameters including higher doses (at least 1.5 to 2.5 times the intramuscular dose), specific concentrations (10-50 mg/mL), and appropriate volumes (1-10 mL) to achieve effective anti-hepatitis B antibody levels. These parameter changes ensure that subcutaneous administration maintains therapeutic effectiveness while enabling patient self-administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The subcutaneous method provides effective anti-hepatitis B antibody levels and timing comparable to intramuscular administration, improving patient compliance and quality of life by reducing pain and hospital visits, while maintaining adequate serum concentrations to prevent hepatitis B recurrence.
Implementation Method 1
incomplete absorption from the subcutaneous space into the intravascular space
Implementation Method 2
absorption from the subcutaneous space into the intravascular space
Data Source
AI summary
The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus.